Josh Smiley

Josh Smiley, the president and COO of Zai Lab, shares insights from his extensive biopharma career. He highlights China's transformation from a follower to a leader in biotech innovation, focusing on oncology and immunology. Smiley discusses Zai Lab's unique approach that merges rapid local execution with global standards, propelling their novel therapies into advanced trials. He emphasizes the strategic advantage for companies integrating China into their global plans early, anticipating a significant impact on the future of drug development and innovation.